Ensuring ample cash reserves to support development of its cancer and inflammatory drug pipeline, Micromet Inc. gained access to up to $25 million through a committed equity financing facility. (BioWorld Today)

Micromet Secures Funding In $25M Financing Facility

Sep. 1, 2006

By Jennifer Boggs

Genzyme Wants AnorMed For $380M; AnorMed Uninterested

Aug. 31, 2006

By Jennifer Boggs

After AnorMed Inc.'s board rejected an unsolicited $380 million takeover bid, Genzyme Corp. said it plans to go to AnorMed shareholders with a proposal to acquire the company. (BioWorld Today)

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...